Mutant-selective thyromimetics for the chemical rescue of thyroid hormone receptor mutants associated with resistance to thyroid hormone

Biochemistry

Volumn 44, Issue 12, 2005, Pages 4612-4626

  Shi, Youheng ^a   Ye, Haifen ^a   Link, Kristian H ^a   Putnam, Marc C ^a   Hubner, Isaac ^a   Dowdell, Sarah ^a   Koh, John T ^a  

^a UNIVERSITY OF DELAWARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOASSAY; BIOLOGICAL ORGANS; DISEASES; GENES; GENETIC ENGINEERING;

HOMEOSTASIS; MUTATION; THYROID HORMONE RECEPTORS (TR); TRANSACTIVATION FUNCTION;

HORMONES;

4 [4 (2 HYDROXYETHOXY) 2,6 DIMETHYLBENZYL] 2 ISOPROPYLPHENOL; 4 [4 (3 HYDROXYPROP 1 YNYL) 2,6 DIMETHYLBENZYL] 2 ISOPROPYLPHENOL; 4 [4 (3 HYDROXYPROPYL) 2,6 DIMETHYLBENZYL] 2 ISOPROPYLPHENOL; 4 [4 (4 HYDROXYBUT 2 YNYLOXY) 2,6 DIMETHYLBENZYL] 2 ISOPROPYLPHENOL; 4 [4 (HYDROXYMETHYL) 2,6 DIMETHYLBENZYL] 2 ISOPROPYLPHENOL; LIOTHYRONINE; THYROID HORMONE DERIVATIVE; THYROID HORMONE RECEPTOR BETA; THYROMIMETIC AGENT; UNCLASSIFIED DRUG;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA RESPONSIVE ELEMENT; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; EMBRYO; GENE ACTIVITY; HUMAN; HUMAN CELL; MUTATION; PRIORITY JOURNAL; RECEPTOR SENSITIVITY; REPORTER GENE; THYROID HORMONE RESISTANCE;

ACETIC ACIDS; ARGININE; CARBOXYLIC ACIDS; CELL LINE; CYSTEINE; DRUG RESISTANCE; GLYCINE; HISTIDINE; HUMANS; LIGANDS; MOLECULAR MIMICRY; MUTAGENESIS, SITE-DIRECTED; PHENOLS; PROMOTER REGIONS (GENETICS); PROTEIN BINDING; RECEPTORS, THYROID HORMONE; REPETITIVE SEQUENCES, NUCLEIC ACID; RESPONSE ELEMENTS; THYROID HORMONE RECEPTORS BETA; THYROTROPIN; TRIIODOTHYRONINE;

EID: 15444367413     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi0482349     Document Type: Article

References (49)

1. Hulbert, A. J. (2000) Thyroid hormones and their effects: A new perspective, Biol. Rev. 75, 519-631.
2. Yen, P. M. (2001) Physiological and molecular basis of thyroid hormone action, Physiol. Rev. 81, 1097-1142.
3. Greenspan, F. S. (1994) in Basic and Clinical Endocrinology (Greenspan, F. S., and Baxter, J. D., Eds.) pp 160-226, Appleton & Lange, Norwalk, VA.
4. Apriletti, J. W., Ribeiro, R. C., Wagner, R. L., Feng, W., Webb, P., Kushner, P. J., West, B. L., Nilsson, S., Scanlan, T. S., Fletterick, R. J., and Baxter, J. D. (1998) Molecular and structural biology of thyroid hormone receptors, Clin. Exp. Pharmacol Physiol., Suppl. 25, S2-S11.
5. Klein, I., and Ojamaa, K. (2001) Mechanisms of disease: Thyroid hormone and the cardiovascular system, N. Engl. J. Med. 344, 501-509.
6. Refetoff, S., Weiss, R. E., and Usala, S. J. (1993) The syndromes of resistance to thyroid hormone, Endocr. Rev. 14, 348-399.
7. Baxter, J. D., Dillmann, W. H., West, B. L., Huber, R., Furlow, J. D., Fletterick, R. J., Webb, P., Apriletti, J. W., and Scanlan, T. S. (2001) Selective modulation of thyroid hormone receptor action, J. Steroid Biochem. Mol. Biol. 76, 31-42.
8. Kahaly, G. J., Matthews, C. H., Mohr-Kahaly, S., Richards, C. A., and Chatterjee, V. K. K. (2002) Cardiac involvement in thyroid hormone resistance, J. Clin. Endocrinol. Metab. 87, 204-212.
9. Baxter, J. D., Webb, P., Grover, G., and Scanlan, T. S. (2004) Selective activation of thyroid hormone signaling pathways by GC-1: A new approach to controlling cholesterol and body weight, Trends Endocrinol. Metab. 15, 154-157.
10. Dupre, S. M., Guissouma, H., Flamant, F., Seugnet, I., Scanlan, T. S., Baxter, J. D., Samarut, J., Demeneix, B. A., and Becker, N. (2004) Both thyroid hormone receptor TR(beta) 1 and TR(beta) 2 isoforms contribute to the regulation of hypothalamic thyrotropin-releasing hormone, Endocrinology 145, 2337-2345.
11. Yen, P. M. (2003) Molecular basis of resistance to thyroid hormone, Trends Endocrinol. Metab. 14, 327-333.
12. Collingwood, T. N., Adams, M., Tone, Y., and Chatterjee, V. K. K. (1994) Spectrum of transcriptional, dimerization, and dominant-negative properties of 20 different mutant thyroid-hormone beta-receptors in thyroid-hormone resistance syndrome, Mol. Endocrinol. 8, 1262-1277.
13. Chatterjee, V. K., Nagaya, T., Madison, L. D., Datta, S., Rentoumis, A., and Jameson, J. L. (1991) Thyroid hormone resistance syndrome. Inhibition of normal receptor function by mutant thyroid hormone receptors, J. Clin. Invest. 87, 1977-1984.
14. Liu, Y., Takeshita, A., Misiti, S., Chin, W. W., and Yen, P. M. (1998) Lack of coactivator interaction can be a mechanism for dominant negative activity by mutant thyroid hormone receptors, Endocrinology 139, 4197-4204.
15. Piedrafita, F. J., Ortiz, M. A., and Pfahl, M. (1995) Thyroid hormone receptor-beta mutants associated with generalized resistance to thyroid hormone show defects in their ligand-sensitive repression function, Mol. Endocrinol. 9, 1533-1548.
16. Takeda, K., Balzano, S., Sakurai, A., DeGroot, L. J., and Refetoff, S. (1991) Screening of nineteen unrelated families with generalized resistance to thyroid hormone for known point mutations in the thyroid hormone receptor beta gene and the detection of a new mutation, J. Clin. Invest. 87, 496-502.
17. Weiss, R. E., Hayashi, Y., Nagaya, T., Petty, K. J., Murata, Y., Tunca, H., Seo, H., and Refetoff, S. (1996) Dominant inheritance of resistance to thyroid hormone not linked to defects in the thyroid hormone receptor alpha or beta genes may be due to a defective cofactor, J. Clin. Endocrinol. Metab. 81, 4196-4203.
18. Yen, P. M., and Cheng, S. Y. (2003) Germline and somatic thyroid hormone receptor mutations in man, J. Endocrinol. Invest. 26, 780-787.
19. Cheng, S. Y. (2003) Thyroid hormone mutations in cancer, Mol. Cell. Endocrinol. 213, 23-30.
20. Ye, H. F., O'Reilly, K. E., and Koh, J. T. (2001) A subtype-selective thyromimetic designed to bind a mutant thyroid hormone receptor implicated in resistance to thyroid hormone, J. Am. Chem. Soc. 123, 1521-1522.
21. Swann, S. L., Bergh, J., Farach-Carson, M. C., Ocasio, C. A., and Koh, J. T. (2002) Structure based design of selective agonists for a rickets-associated mutant of the vitamin d receptor, J. Am. Chem. Soc. 124, 13795-13805.
22. Swann, S. L., Bergh, J. J., Farach-Carson, M. C., and Koh, J. T. (2002) Rational design of vitamin D3 analogs which selectively restore activity to a vitamin D receptor mutant associated with rickets, Org. Lett. 4, 3863-3866.
23. Gardezi, S. A., Nguyen, C., Malloy, P. J., Posner, G. H., Feldman, D., and Peleg, S. (2001) A rationale for treatment of hereditary vitamin D-resistant rickets with analogs of 1 alpha,25-dihydroxyvitamin D-3, J. Biol. Chem. 276, 29148-29156.
24. Takeda, T., Suzuki, S., Liu, R. T., and DeGroot, L. J. (1995) Triiodothyroacetic acid has unique potential for therapy of resistance to thyroid hormone, J. Clin. Endocrinol. Metab. 80, 2033-2040.
25. Hayashi, Y., Sunthornthepvarakul, T., and Refetoff, S. (1994) Mutations of CpG dinucleotides located in the triiodothyronine (t-3)-binding domain of the thyroid-hormone receptor TR(beta)-gene that appears to be devoid of natural mutations may not be detected because they are unlikely to produce the clinical phenotype of resistance to thyroid-hormone, J. Clin. Invest. 94, 607-615.
26. McMartin, C., and Bohacek, R. S. (1997) Qxp: Powerful, rapid computer algorithyms for structure-based drug design, J. Comput.-Aided Mol. Des. 11, 333-344.
27. Darimont, B. D., Wagner, R. L., Apriletti, J. W., Stallcup, M. R., Kushner, P. J., Baxter, J. D., Fletterick, R. J., and Yamamoto, K. R. (1998) Structure and specificity of nuclear receptor-coactivator interactions, Genes Dev. 12, 3343-3356.
28. Wagner, R. L., Huber, B. R., Shiau, A. K., Kelly, A., Lima, S. T. C., Scanlan, T. S., Apriletti, J. W., Baxter, J. D., West, B. L., and Fletterick, R. J. (2001) Hormone selectivity in thyroid hormone receptors, Mol. Endocrinol. 15, 398-410.
29. Wagner, R., Apriletti, J. W., McGarth, M. E., West, B. L., Baxter, J. D., and Fletterick, R. J. (1995) A structural role for hormone in the thyroid hormone receptor, Nature 378, 690-697.
30. Chiellini, G., Apriletti, J. W., al Yoshihara, H., Baxter, J. D., Ribeiro, R. C., and Scanlan, T. S. (1998) A high-affinity subtype-selective agonist ligand for the thyroid hormone receptor, Chem. Biol. 5, 299-306.
31. Scafonas, A., Wolfgang, C. L., Gabriel, J. L., Soprano, K. J., and Soprano, D. R. (1997) Differential role of homologous positively charged amino acid residues for ligand binding in retinoic acid receptor alpha compared with retinoic acid receptor beta, J. Biol. Chem. 272, 11244-11249.
32. Weatherman, R. V., Fletterick, R. J., and Scanlan, T. S. (1999) Nuclear-receptor ligands and ligand-binding domains, Annu. Rev. Biochem. 68, 559-581.
33. Burris, T. P., and McCabe, E. R. B. (2001) Nuclear Receptors and Genetic Disease, Academic Press, San Diego.
34. Huber, B. R., Desclozeaux, M., West, B. L., Cunha-Lima, S. T., Nguyen, H. T., Baxter, J. D., Ingraham, H. A., and Fletterick, R. J. (2003) Thyroid hormone receptor-beta mutations conferring hormone resistance and reduced corepressor release exhibit decreased stability in the n-terminal ligand-binding domain, Mol. Endocrinol. 17, 107-116.
35. Huber, B. R., Sandler, B., West, B. L., Lima, S. T. C., Nguyen, H. T., Apriletti, J. W., Baxter, J. D., and Fletterick, R. J. (2003) Two resistance to thyroid hormone mutants with impaired hormone binding, Mol. Endocrinol. 17, 643-652.
36. Chiellini, G., Nguyen, N. H., Apriletti, J. W., Baxter, J. D., and Scanlan, T. S. (2002) Synthesis and biological activity of novel thyroid hormone analogues: 5′-aryl substituted GC-1 derivatives, Bioorg. Med. Chem. 10, 333-346.
37. Yoshihara, H. A. I., Apriletti, J. W., Baxter, J. D., and Scanlan, T. S. (2003) Structural determinants of selective thyromimetics, J. Med. Chem. 46, 3152-3161.
38. Hammarstrom, P., Wiseman, R. L., Powers, E. T., and Kelly, J. W. (2003) Prevention of transtyretin amyloid disease by changing protein misfolding energetics, Science 299, 713-716.
39. Foster, B. A., Coffey, H. A., Morin, M. J., and Rastinejad, F. (1999) Pharmacological rescue of mutant p53 conformation and function, Science 286, 2507-2510.
40. Noorwez, S. M., Kuksa, V., Imanishi, Y., Shu, L., Filipek, S., Palczewski, K., and Kauushal, S. (2003) Pharmacological chaperonemediated in vivo folding and stabilization of the p23h-opsin mutant associated with autosomal dominant retinitis pigmentosa, J. Biol. Chem. 278, 14442-14450.
41. Bernier, V., Lacace, M., Bichet, D. G., and Bouvier, M. (2004) Pharmacological chaperones: Potential treatment for conformational diseases, Trends Endocrinol. Metab. 15, 222-228.
42. Radetti, G., Persani, L., Molinaro, G., Mannavola, D., Cortelazzi, D., Chatterjee, V. K. K., and BeckPeccoz, P. (1997) Clinical and hormonal outcome after two years of triiodothyroacetic acid treatment in a child with thyroid hormone resistance, Thyroid 7, 775-778.
43. Asteria, C., Rajanayagam, O., Collingwood, T. N., Persani, L., Romoli, R., Mannavola, D., Zamperini, P., Buzi, F., Ciralli, F., Chatterjee, V. K. K., and Beck-Peccoz, P. (1999) Prenatal diagnosis of thyroid hormone resistance, J. Clin. Endocrinol. Metab. 84, 405-410.
44. Nagaya, T., Eberhardt, N. L., and Jameson, J. L. (1993) Thyroid-hormone resistance syndrome-correlation of dominant-negative activity and location of mutations, J. Clin. Endocrinol. Metab. 77, 982-990.
45. Nagaya, T., and Jameson, J. L. (1993) Thyroid-hormone receptor dimerization is required for dominant-negative inhibition by mutations that cause thyroid-hormone resistance, J. Biol. Chem. 268, 15766-15771.
46. Hao, E. H., Menke, J. B., Smith, A. M., Jones, C., Geffner, M. E., Hershman, J. M., Wuerth, J. P., Samuels, H. H., Ways, D. K., and Usala, S. J. (1994) Divergent dimerization properties of mutant beta-1 thyroid-hormone receptors are associated with different dominant-negative activities, Mol. Endocrinol. 8, 841-851.
47. Szapary, D., Huang, Y., and Simons, S. S., Jr. (1999) Opposing effects of corepressor and coactivators in determining the dose-response curve of agonists, and residual agonist activity of antagonists, for glucocorticoid receptor-regulated gene expression, Mol. Endocrinol. 13, 2108-2121.
48. Loven, M. A., Likhite, V. S., Choi, I., and Nardulli, A. M. (2001) Estrogen response elements alter coactivator recruitment through allosteric modulation of estrogen receptor beta conformation, J. Biol. Chem. 276, 45282-45288.
49. Wood, J. R., Likhite, V. S., Loven, M. A., and Nardulli, A. M. (2001) Allosteric modulation of estrogen receptor conformation by different estrogen response elements, Mol. Endocrinol. 15, 1114-1126.